Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-01

Study Completion Date

2009-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Airway macrophage impairment is a central feature in the immunopathogenesis of chronic obstructive pulmonary disease, regardless of smoking status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function

NCT00281190

Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive

COMPLETED

Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease

NCT02551614

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE1

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

NCT02913365

Hemoptysis Haemoptysis Lung Disease +17 more

UNKNOWN

Phenotypic Characterization of Alveolar Macrophages 2016 (Caract-Aires-2016)

NCT03250897

Lung Diseases

UNKNOWN

Functional Proteomics of Alveolar Macrophages

NCT00806091

COPD

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the United States, a variety of farming operations can generate significant amounts of dust. Chronic organic dust exposure to workers in this industry can result in several respiratory health conditions including chronic bronchitis, chronic obstructive pulmonary disease (COPD), and exacerbations of asthma. Organic dust is a complex mixture containing particulate matter and microbial-associated components from gram positive and gram negative bacteria. Airway macrophages are key innate immune cells that are rapidly activated by exposure to inhaled toxins and organic dust.

The literature indicates that subjects with tobacco-induced chronic bronchitis/COPD have alveolar macrophages that have impaired function. It has been hypothesized that the impaired lung macrophage function may contribute to the increased susceptibility to infections and chronic bacterial colonization that is a central feature in subjects with chronic bronchitis/COPD. It is unknown at this time if impaired macrophage function is secondary to tobacco-induced effects, or is a central pathologic feature of chronic bronchitis/COPD.

We will explore the expression of innate immune cell surface molecule expression involved in antigen presentation, phagocytic ability, and ex vivo cytokine responses in airway macrophages obtained by induced sputum. We will also collect blood to determine if ex vivo stimulation of blood mimics the inflammatory responses observed with airway macrophages. Comparisons to our past findings in vitro studies, which demonstrated that repetitive organic dust exposure impairs monocyte derived macrophage immune cell surface markers and function, could then be made. This information could lead to future investigations centered on therapeutic interventions to prevent or reverse the underlying lung disease experienced by farmers in this industry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive Bronchitis, Chronic Occupational Diseases Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group One

Healthy non-smoking controls

No interventions assigned to this group

Group Two

Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease

No interventions assigned to this group

Group Three

Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medically stable to participate in induced sputums
* Group One: Smoked less than 100 cigarettes in their lifetime Quit smoking greater than 10 years ago Pre-bronchodilator FEV1/FVC \> 70% Pre-bronchodilator FEV1 % predicted \> 80%
* Group Two: Greater than a 20-pack year tobacco history Smoked in the last two years Post-bronchodilator FEV1/FVC \< 70%
* Group Three:Have less than a 20-pack year tobacco history Quit smoking greater than 20 years ago Post-bronchodilator FEV1/FVC \< 70%

Exclusion Criteria

* Personal history of lung cancer
* Pregnancy
* Personal history of autoimmune disease
* Currently taking oral/parental corticosteroids
* Personal history of upper or lower respiratory tract infection in the prior four weeks

Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes